Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

Rhea-AI Summary

Silo Pharma (NASDAQ:SILO) has entered into a non-binding letter of intent with Hoth Therapeutics (NASDAQ:HOTH) to form a 50:50 joint venture targeting the $16 billion global obesity market. The collaboration focuses on developing a novel therapeutic platform based on glial cell line-derived neurotrophic factor (GDNF), exclusively licensed from the U.S. Department of Veterans Affairs and co-developed with Emory University.

The technology, protected under U.S. Patent No. 10,052,362, targets multiple conditions including obesity, non-alcoholic fatty liver disease (NAFLD), and type 2 diabetes. The partnership combines Hoth's regulatory expertise with Silo's translational capabilities to address a significant unmet need, as obesity affects over 40% of U.S. adults, with veterans being particularly impacted.

Positive

• Exclusive U.S. license from VA for a potential breakthrough obesity treatment
• Equal 50:50 joint venture structure with Hoth Therapeutics
• Technology protected by U.S. Patent targeting $16 billion market
• Addresses multiple high-value indications including obesity, NAFLD, and type 2 diabetes

Negative

• Letter of intent is non-binding, indicating deal uncertainty
• Technology still in preclinical stage with no human trial data
• Faces competition in crowded obesity treatment market
• Development and commercialization timeline uncertain

News Market Reaction

+4.08%

1 alert

+4.08% News Effect

On the day this news was published, SILO gained 4.08%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Technology Co-Developed by the U.S. Department of Veterans Affairs and Emory University

NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into a non-binding letter of intent to form a strategic 50:50 joint venture with Hoth Therapeutics, Inc. (Nasdaq: HOTH) to develop and commercialize a potential treatment for obesity and metabolic disease based on technology Hoth has exclusively licensed from the U.S. Department of Veterans Affairs (VA) that was co-developed by the VA and Emory University.

The novel therapeutic platform centers on glial cell line-derived neurotrophic factor (GDNF), a VA-invented biologic with demonstrated anti-obesity effects and metabolic regulation in preclinical models. The platform is protected under U.S. Patent No. 10,052,362 and targets multiple high-burden conditions, including non-alcoholic fatty liver disease (NAFLD), type 2 diabetes, and central obesity.

“With obesity at epidemic levels and no curative therapies available, we believe the VA’s biologic GDNF is potentially a game-changer,” said Eric Weisblum, CEO of Silo Pharma. “We believe that our potential JV collaboration with Hoth aligns with our mission to accelerate groundbreaking science into human trials.”

“This VA-originated obesity technology has the potential to disrupt a $16 billion market and deliver life-changing impact for millions, including veterans disproportionately affected by metabolic disorders,” added Robb Knie, CEO of Hoth Therapeutics. “We are proud to partner with Silo Pharma in an effort to bring this innovation to the public.”

Deal Highlights:

	●	Exclusive U.S. License from the U.S. Department of Veterans Affairs covering all fields of use
	●	50/50 joint venture structure with equal equity and governance participation
	●	Lead indication: Obesity and NAFLD — conditions with prevalence among both civilian and veteran populations

Unmet Need:
Obesity affects over 40% of U.S. adults and is a leading risk factor for diabetes, cardiovascular disease, and liver failure. Veterans are especially impacted due to chronic inflammation, PTSD-linked metabolic disruption, and access challenges to effective care. There are no approved curative biologics targeting the neuroinflammatory root of obesity, a gap that this VA-originated technology is uniquely positioned to fill.

Strategic Alignment:
The partnership leverages:

	●	The clinical infrastructure and public mission of the VA
	●	Hoth’s regulatory and development expertise
	●	Silo’s translational capabilities and capital efficiency

About Silo Pharma 

Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company focused on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com

Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.

Contact
800-705-0120
investors@silopharma.com

FAQ

What is the joint venture agreement between Silo Pharma (NASDAQ:SILO) and Hoth Therapeutics?

Silo Pharma and Hoth Therapeutics have entered into a non-binding letter of intent to form a 50:50 joint venture to develop and commercialize a VA-licensed obesity treatment technology based on GDNF.

What is the market potential for SILO's obesity treatment technology?

The technology targets a $16 billion global obesity market, addressing multiple conditions including obesity, NAFLD, and type 2 diabetes, with over 40% of U.S. adults affected by obesity.

What technology is SILO using for their obesity treatment?

The treatment is based on glial cell line-derived neurotrophic factor (GDNF), a VA-invented biologic protected under U.S. Patent No. 10,052,362, showing anti-obesity effects in preclinical models.

How will the partnership between SILO and Hoth Therapeutics work?

The partnership will be a 50:50 joint venture combining Hoth's regulatory expertise with Silo's translational capabilities, with equal equity and governance participation from both companies.

What stage of development is SILO's obesity treatment currently in?

The treatment is currently in the preclinical stage, with demonstrated anti-obesity effects and metabolic regulation in preclinical models.